FDA Approves First Gene Therapy Treatment for Sanfilippo Syndrome Type A
Medical researchers and clinicians are celebrating a historic milestone in pediatric medicine following the official Food and Drug Administration (FDA) approval of FAYUVI, the very first gene therapy designed specifically to treat Sanfilippo syndrome type A. The monumental regulatory decision arrives after decades of dedicated scientific inquiry and clinical trials, offering renewed hope to families affected by a condition that has historically lacked any approved medical interventions.
According to announcements from the Abigail Wexner Research Institute at Nationwide Children’s Hospital, the breakthrough treatment is authorized for pediatric patients diagnosed with mucopolysaccharidosis type IIIA (MPS IIIA), more commonly known as Sanfilippo syndrome type A. The development of this therapy represents the culmination of extensive work originating in the institution’s Jerry R. Mendell Center for Gene Therapy.
Understanding Sanfilippo Syndrome Type A
Sanfilippo syndrome type A is classified as an ultrarare lysosomal storage disease, estimated to affect approximately 1 in every 70,000 live births. It stands out as the most severe variant among a group of four distinct lysosomal storage disorders. The underlying pathology involves a deficiency in a vital enzyme caused by mutations within the SGSH gene. This genetic defect sparks a harmful accumulation of complex polysaccharides inside the body’s cells.
While infants carrying the condition typically appear completely healthy at birth, they soon experience profound, progressive developmental delays and severe neurological complications. The disease heavily impacts both the brain and the spinal cord, leading to extensive neuronal dysfunction and neuron loss that ultimately results in early childhood mortality. Until this recent regulatory approval, healthcare providers could only offer supportive care rather than a targeted treatment.
Innovative Gene-Replacement Mechanism
The newly approved therapy, FAYUVI, utilizes an advanced adeno-associated virus serotype 9 (AAV9) vector to tackle the root cause of the disorder. Co-invented by investigators Douglas McCarty, Ph.D., and Haiyan Fu, Ph.D., during their tenure at the Mendell Center for Gene Therapy, the innovative medical product packs a healthy, functional copy of the entire SGSH gene into the viral delivery vehicle.
Medical teams administer the treatment via a straightforward intravenous infusion. This delivery method allows the viral vector to efficiently transport the necessary genetic instructions to cells located both inside and outside the central nervous system, effectively addressing systemic manifestations of the disease.
Paving the Way for Clinical Access
The journey toward regulatory approval required sustained dedication from clinical investigators. Dr. Kevin Flanigan, director of the Jerry R. Mendell Center for Gene Therapy at the Abigail Wexner Research Institute, spearheaded the landmark first clinical trial testing a systemic gene therapy approach for this condition. Dr. Flanigan noted that dosing the initial study participant back in 2016 marked the beginning of a long path toward bringing a viable therapeutic option to clinic waiting rooms.
Following successful clinical evaluations, commercial rights to the therapy program transitioned through industry partners, moving to Abeona Therapeutics in 2013 and subsequently to Ultragenyx in 2022, before achieving final FDA authorization. Moving forward, Nationwide Children’s Hospital is slated to serve as a qualified treatment center. It will join a specialized network of select medical facilities across the United States equipped with the advanced infrastructure and specially trained personnel required to safely administer FAYUVI to vulnerable young patients.
Medical experts emphasize that while this approval marks a monumental turning point for rare genetic disorders, ongoing post-market surveillance and specialized care delivery remain essential as eligible children begin receiving the therapy at designated clinical centers nationwide.
Source: Medical Xpress
